Juno__global_genomic_survey_of_Streptococcus_agalactiae-sc-5903
Juno__global_genomic_survey_of_Streptococcus_agalactiae
Whole genome seqeucning of approximately 10,000 Streptococcus agalactiae genomes to deteremine the global genetic diversity of this species and generate data to inform disease intervention strategies  This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
Group B Streptococcus (GBS, a.k.a. Streptococcus agalactiae) is an opportunistic pathogen and a major cause of neonatal invasive disease, with a particular impact on infant mortality in low and middle-income countries (LMICs), where disease prevention strategies are less often implemented or have low coverage. In this study, we will conduct a whole genome sequence analysis of GBS isolates from across a broad geographical and temporal span with the central aim of informing disease intervention strategies. Analysis of whole genome sequence data has the potential to provide clear answers to many of the important questions around GBS disease and vaccine development. The three key areas that we need to understand to reduce the global burden of GBS disease are pathogen diversity, pathogen genetic associations with the disease and pathogen transmission